探討有絲分裂標記Anti-phospho-Histone H3在大腸直腸癌的表現與預後因子的相關性

Expression of Mitosis Marker Anti-phospho-Histone H3 in Human Colorectal Cancer and correlation with classic Prognostic Factor

鞠沅東(Yuan-Tung Chu)

指導教授 ： 王淑慧

國立臺灣大學/醫學院/解剖學暨細胞生物學研究所/碩士(2015年)

https://doi.org/10.6342/NTU.2015.02515

摘要

大腸直腸癌是在世界上最主要的惡性腫瘤死亡原因而且病因牽涉多重複雜的步驟和因子。因此，鑑別有用的預後標記將有利於發展對大腸直腸癌合理的治療策略。磷酸化組織蛋白H3(phospho-Histone H3, PHH3)是一個新的定量有絲分裂的免疫組織化學染色標記。然而，PHH3有關大腸直腸癌預後的訊息很十分有限。本實驗的主要目的探索PHH3在大腸直腸癌預後扮演的角色，探討新細胞分化標記PHH3和已確立的細胞分化標記Ki-67和腫瘤抑制蛋白p53標記之間的相關性和判斷它們與大腸直腸癌預後的關聯性。
在本實驗有164病例根據蘇木紫-伊紅染色(Hematoxylin & Eosin stain) 和PHH3、 Ki-67和p53的免疫組織化學染色方法分析臨床病理參數。根據研究結果顯示，與鄰近正常大腸黏膜相比PHH3在腫瘤表現有顯著的增加。PHH3的表現與大腸直腸癌分化(P<0.05)、臨床分期(P<0.05)、神經侵犯(P<0.001)、M分期(P<0.05)有顯著意義。
在存活分析中，與低PHH3表現的病例相比，高PHH3表現較長的整體存活和較好的無轉移存活率。依據價值評估，與Ki-67和p53相比PHH3有較高的預後價值，而且有常規實驗診斷的潛在價值。
PHH3的表現與大腸直腸癌的發生和進展有顯著的相關性。或許PHH3可能建立一個預防大腸直腸癌有用的分子標的或引導改善治療大腸直腸癌的治療方法。PHH3可能是一個有用的預測大腸直腸癌疾病結果的預測因子。

關鍵字

磷酸化組織蛋白H3 ； 大腸直腸癌 ； p53 ； Ki-67

並列摘要

Colorectal cancer (CRC) has a complex pathogenesis involving multiple steps and factors, and is one of the most common causes of cancer deaths worldwide. Thus, the identification of useful prognostic markers that exert a strong prognostic impact for CRC progression would be beneficial in the development of rational therapeutic strategies. Phosphohistone H3 (PHH3) is a new marker for quantifying mitoses; however, there is limited information on the prognostic value of PHH3 in patients with CRC. The aim of the current study was to determine the role of PHH3 as a prognostic factor in patients with CRC and to elucidate the relationships between the novel proliferation marker, PHH3, the established cell proliferating marker, Ki-67, and the tumor suppressor, p53, and the prognostic relevance in patients CRC.
One hundred sixty-four CRC patients were included in the current study. Clinicopathologic parameters were analyzed by H&E staining and immunohistochemical staining for PHH3, Ki-67, and p53. The expression of PHH3 was significantly increased in CRC tissues compared to adjacent normal colorectal mucosal tissues. PHH3 expression was significantly associated with CRC differentiation (P<0.05), clinical staging (P<0.05), perineural invasion (P<0.001), and metastasis (p< 0.05). Patients with high PHH3 expression had longer overall survival and better metastasis-free survival rates than patients with low PHH3 expression. PHH3 had a greater prognostic value than Ki-67 and p53 in CRC patients, and thus potential for use in routine diagnostic laboratories.
The expression of PHH3 is highly related to CRC detection and significantly correlated to the progression of CRC. PHH3 may constitute a useful molecular target for CRC prevention or may led to improved therapeutic modalities for this common cancer. PHH3 may be a useful prognostic factor for the prediction of disease outcome in patients with CRC.

並列關鍵字

phospho-Histone H3 ； colorectal cancer ； p53 ； ki-67

參考文獻

1.Rebecca Siegel, Deepa Naishadham, and Ahmedin Jemal, Cancer statistics. CA Cancer J Clin. 2013; 63(1):11-30.

2.Sylvain Manfredi, Coˆme Lepage, Cyril Hatem, and Olivier Coatmeur. Epidemiology and Management of Liver Metastases from Colorectal Cancer. Ann Surg. 2006; 244: 254–259.

3.Jeffrey A. Meyerhardt, and Robert J. Mayer. Systemic Therapy for Colorectal Cancer. N Engl J Med, 2005; 352:476-487.

4.Markowitz SD, Bertagnolli MM. Molecular origins of cancer: Molecular basis of colorectal cancer. N Engl J Med.2009; 361(25):2449-2460.

5.Van Engeland M, Derks S, Smits KM, Meijer GA, Herman JG. Colorectal cancer epigenetics: complexmplicitsiy. J Clin Oncol. 2011; 29(10):1382-1391.